NASDAQ:ANCNANCHIANO THERAP/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ANCHIANO THERAP/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.98 +0.01 (+1.33 %) (As of 08/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.91Now: $0.98▼$1.0150-Day Range$0.78MA: $1.27▼$1.6852-Week Range$0.51Now: $0.98▼$3.33Volume129,282 shsAverage Volume59,140 shsMarket Capitalization$7.27 millionP/E RatioN/ADividend YieldN/ABeta0.97 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesSocial Media Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingANCHIANO THERAP/S has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, ANCHIANO THERAP/S has a potential upside of 1,532.5% from its current price of $0.98.Amount of Analyst CoverageANCHIANO THERAP/S has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesANCHIANO THERAP/S has received 56 “outperform” votes. (Add your “outperform” vote.)Underperform VotesANCHIANO THERAP/S has received 57 “underperform” votes. (Add your “underperform” vote.)Community SentimentANCHIANO THERAP/S has received 50.44% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ANCHIANO THERAP/S and other stocks. Vote “Outperform” if you believe ANCN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ANCN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldANCHIANO THERAP/S does not currently pay a dividend.Dividend GrowthANCHIANO THERAP/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ANCHIANO THERAP/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.88% of the stock of ANCHIANO THERAP/S is held by insiders.Percentage Held by InstitutionsOnly 7.49% of the stock of ANCHIANO THERAP/S is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ANCHIANO THERAP/S are expected to decrease in the coming year, from ($2.25) to ($3.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANCHIANO THERAP/S is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ANCHIANO THERAP/S is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioANCHIANO THERAP/S has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.23 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANCN Previous Symbol CUSIPN/A CIKN/A Webwww.anchiano.com Phone857-259-4622Debt Debt-to-Equity Ratio0.01 Current Ratio4.23 Quick Ratio4.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book0.49Profitability EPS (Most Recent Fiscal Year)($3.46) Net Income$-27,120,000.00 Net MarginsN/A Return on Equity-54.04% Return on Assets-33.83%Miscellaneous Employees19 Outstanding Shares7,420,000Market Cap$7.27 million Next Earnings DateN/A OptionableNot Optionable $0.98 +0.01 (+1.33 %) (As of 08/3/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ANCN News and Ratings via Email Sign-up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. ANCHIANO THERAP/S (NASDAQ:ANCN) Frequently Asked Questions How has ANCHIANO THERAP/S's stock been impacted by COVID-19 (Coronavirus)? ANCHIANO THERAP/S's stock was trading at $0.8191 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ANCN stock has increased by 19.7% and is now trading at $0.9801. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ANCHIANO THERAP/S? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANCHIANO THERAP/S in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ANCHIANO THERAP/S. How were ANCHIANO THERAP/S's earnings last quarter? ANCHIANO THERAP/S (NASDAQ:ANCN) posted its earnings results on Thursday, May, 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.55) by $0.14. View ANCHIANO THERAP/S's earnings history. What price target have analysts set for ANCN? 3 brokers have issued twelve-month target prices for ANCHIANO THERAP/S's shares. Their forecasts range from $16.00 to $16.00. On average, they expect ANCHIANO THERAP/S's share price to reach $16.00 in the next year. This suggests a possible upside of 1,532.5% from the stock's current price. View analysts' price targets for ANCHIANO THERAP/S. Has ANCHIANO THERAP/S been receiving favorable news coverage? News headlines about ANCN stock have trended somewhat positive recently, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ANCHIANO THERAP/S earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about ANCHIANO THERAP/S. Who are some of ANCHIANO THERAP/S's key competitors? Some companies that are related to ANCHIANO THERAP/S include Intec Pharma (NTEC), AzurRx BioPharma (AZRX), Kazia Therapeutics (KZIA), Provectus Biopharmaceuticals (PVCT), PLx Pharma (PLXP), KemPharm (KMPH), Neurotrope (NTRP), Spring Bank Pharmaceuticals (SBPH), American Bio Medica (ABMC), Aptevo Therapeutics (APVO), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Mateon Therapeutics (MATN), Cyclacel Pharmaceuticals (CYCC), IntelGenx Technologies (IGXT) and Pharmaxis (PXSLY). View all competitors. What other stocks do shareholders of ANCHIANO THERAP/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other ANCHIANO THERAP/S investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Amplify Energy (AMPY), Amplify Energy (AMPY), Algonquin Power & Utilities (AQN), BCE (BCE), Franklin Resources (BEN), Bank of Nova Scotia (BNS), British American Tobacco (BTI) and Carnival (CCL). Who are ANCHIANO THERAP/S's key executives? ANCHIANO THERAP/S's management team includes the following people: Dr. Frank G. Haluska, Pres, CEO & Director (Age 60)Mr. Jonathan Burgin, CFO & COO (Age 58)Mr. Ronald K. Knickerbocker, Sr. VP of Clinical Devel. & Data Sciences (Age 53)Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer (Age 81)Dr. Michal Gilon Ohev-Zion, VP of R&D (Age 41) When did ANCHIANO THERAP/S IPO? (ANCN) raised $35 million in an IPO on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager. What is ANCHIANO THERAP/S's stock symbol? ANCHIANO THERAP/S trades on the NASDAQ under the ticker symbol "ANCN." How do I buy shares of ANCHIANO THERAP/S? Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ANCHIANO THERAP/S's stock price today? One share of ANCN stock can currently be purchased for approximately $0.98. How big of a company is ANCHIANO THERAP/S? ANCHIANO THERAP/S has a market capitalization of $7.27 million. The company earns $-27,120,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. ANCHIANO THERAP/S employs 19 workers across the globe. What is ANCHIANO THERAP/S's official website? The official website for ANCHIANO THERAP/S is www.anchiano.com. How can I contact ANCHIANO THERAP/S? ANCHIANO THERAP/S's mailing address is ONE KENDALL SQUARE BUILDING 400 SUITE 14-105, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-4622 or via email at [email protected] This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
